Sarepta’s Elevidys Is Likely to Remain on Market, JPMorgan Says

Sarepta Therapeutics’ Elevidys is likely to remain on the market, according to JPMorgan analyst Anupam Rama, who sees upside from current levels if that’s the case.

Read more: Sarepta Sinks Amid FDA Halt Request, Clinical Hold: Street Wrap

• Rama — who holds a buy-equivalent rating on Sarepta — says commentary at the bottom of the FDA’s press release suggests Elevidys is staying on the market for ambulatory patients
  • “We would note there have been no patient deaths in ambulatory patients to date,” Rama writes
  • Says if an ambulatory patient death were to occur due to acute liver injury ...